

Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with Markings to Show Changes**".

Respectfully submitted,



William T. Han  
Attorney for Applicant  
Registration No. 34,344

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5219  
Facsimile (610) 270-5090

n:\han\apps\p32221\preliminary amendment.doc

**VERSION WITH MARKINGS TO SHOW CHANGES**

**IN THE SPECIFICATION:**

**The paragraph beginning at page 3, line 14, has been amended as follows:**

-- Further suitable response elements include ATTTCCCCGAAAT (SEQ ID NO:1) (human and murine IRF-1, Pine, R., Canova, A. and Schindler, C. (1994) EMBO J. 13, 158-167.), ATTTCCCGTAAAT (SEQ ID NO:2) (human serum inducible element from the c-fos promoter, Zhong, Z., Wen, Z. and Darnell, J.E. Jr. (1994) Science 264, 95-98) ACTTCTTGGAATT (SEQ ID NO:3) (rat  $\beta$ -casein, Schindler, C., Kashleva, H., Pernis, A., Pine, R. and Rothman, P (1994) EMBO J. 13, 1350-1356) and ACTTCTAGGAATT (SEQ ID NO:4) (bovine  $\beta$ -casein, Schindler, C., Kashleva, H., Pernis, A., Pine, R. and Rothman, P (1994) EMBO J. 13, 1350-1356). --

**The paragraph beginning at page 7, line 22, has been amended as follows:**

-- The particular endothelial cells are transfected with a reporter plasmid, pGL2-basic luciferase vector (Promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, ATTTCCCGTAAAT (SEQ ID NO:2), upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, **52**, 456). To correct for differences in transfection efficiency, the cells can be co-transfected with a reference plasmid expressing  $\beta$ -galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound or ob-protein alone as a positive control and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate  $\beta$ -galactosidase, activity. Antagonist activity can be assayed by pre- or co-addition of an appropriate concentration of ob-protein to the compound under evaluation and measuring the reduction in luciferase response relative to that of ob-protein alone. Standard methods exist for assaying luciferase enzyme activity for example Ow et al., *Science*, 1986, **234**, 856 and de Wet et al., *Mol. Cell Biol.*, 1987, **7**, 725. as well as several commercial kits. --

**IN THE CLAIMS:**

**Claims 10 and 11 have been amended as follows:**

10. (Amended) A method according to claim 9, wherein the response element is TTCCCGGAA (SEQ ID NO:5).

11. (Amended) A method according to claim 9, wherein the response element is selected from: ATTTCCCCGAAAT (SEQ ID NO:1), ATTTCCCGTAAAT (SEQ ID NO:2), ACTTCTTGGAATT (SEQ ID NO:3) and ACTTCTAGGAATT (SEQ ID NO:4).